Abstract
Tumor-specific neo-antigens that arise as a consequence of mutations are thought to be important for the therapeutic efficacy of cancer immunotherapies. Accumulating evidence suggests that neo-antigens may be commonly recognized by intratumoral CD8+ T cells, but it is unclear whether neo-antigen-specific CD4+ T cells also frequently reside within human tumors. In view of the accepted role of tumor-specific CD4+ T-cell responses in tumor control, we addressed whether neo-antigen-specific CD4+ T-cell reactivity is a common property in human melanoma.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antigen Presentation / immunology
-
Antigens, Neoplasm / immunology
-
CD4-Positive T-Lymphocytes / immunology*
-
CD8-Positive T-Lymphocytes / immunology*
-
Cell Line, Tumor
-
DNA-Binding Proteins / genetics
-
Epitopes, T-Lymphocyte / genetics
-
Epitopes, T-Lymphocyte / immunology*
-
Humans
-
Immunotherapy*
-
Melanoma / genetics
-
Melanoma / immunology*
-
Melanoma / pathology
-
Mutation
-
Proto-Oncogene Proteins c-bcl-6
-
bcl-X Protein / genetics
Substances
-
Antigens, Neoplasm
-
BCL2L1 protein, human
-
BCL6 protein, human
-
DNA-Binding Proteins
-
Epitopes, T-Lymphocyte
-
Proto-Oncogene Proteins c-bcl-6
-
bcl-X Protein